PHARMOSA BIOPHARM INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 68 TWD | -0.58% |
|
-4.36% | -22.73% |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 7,055 | 10,314 |
| Enterprise Value (EV) 1 | 6,404 | 9,484 |
| P/E ratio | -23.5 x | 1,257 x |
| Yield | - | - |
| Capitalization / Revenue | - | 32,794,761 x |
| EV / Revenue | - | 30,156,637 x |
| EV / EBITDA | -24 x | 3,173 x |
| EV / FCF | -38,757,885 x | -188,285,813 x |
| FCF Yield | -0% | -0% |
| Price to Book | 9.27 x | 9.07 x |
| Nbr of stocks (in thousands) | 110,934 | 117,204 |
| Reference price 2 | 63.60 | 88.00 |
| Announcement Date | 4/21/23 | 3/28/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales | - | - | - | 314.5 |
| EBITDA 1 | -184.2 | -254.7 | -266.3 | 2.989 |
| EBIT 1 | -187.4 | -259.1 | -271.5 | -2.824 |
| Operating Margin | - | - | - | -0.9% |
| Earnings before Tax (EBT) 1 | -181.7 | -256.5 | -266.5 | 8.456 |
| Net income 1 | -181.7 | -256.5 | -266.5 | 8.456 |
| Net margin | - | - | - | 2.69% |
| EPS 2 | -3.820 | -3.020 | -2.705 | 0.0700 |
| Free Cash Flow | - | -136 | -165.2 | -50.37 |
| FCF margin | - | - | - | -16.02% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 4/21/22 | 4/21/22 | 4/21/23 | 3/28/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | 290 | 424 | 651 | 830 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | -136 | -165 | -50.4 |
| ROE (net income / shareholders' equity) | - | -54.7% | -41.2% | 0.89% |
| ROA (Net income/ Total Assets) | - | -28.7% | -24.5% | -0.17% |
| Assets 1 | - | 894.5 | 1,088 | -5,112 |
| Book Value Per Share 2 | 8.120 | 5.430 | 6.860 | 9.710 |
| Cash Flow per Share 2 | 8.290 | 4.720 | 6.060 | 8.310 |
| Capex 1 | 7.05 | 3.06 | 10.2 | 81.5 |
| Capex / Sales | - | - | - | 25.9% |
| Announcement Date | 4/21/22 | 4/21/22 | 4/21/23 | 3/28/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -22.73% | 270M | |
| +18.97% | 45.34B | |
| +42.78% | 40.42B | |
| -10.06% | 37.92B | |
| +31.15% | 31.75B | |
| -7.79% | 27.71B | |
| +13.32% | 26.52B | |
| +43.05% | 13.96B | |
| +31.28% | 12.44B | |
| -7.41% | 11.26B |
- Stock Market
- Equities
- 6875 Stock
- Financials Pharmosa Biopharm Inc.
